Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NHS Digital Health Check

- PMLiVE

NHS seeks ‘solution creators’ from within pharma

Health service is moving to a 'new era' of industry relations, says NHS England

- PMLiVE

Wilmington Healthcare survey finds many doctors fear the NHS will fall victim to another ransomware attack

Following the ransomware attack that wreaked havoc on NHS IT systems last year and resulted in major disruption to patient care, the majority of doctors surveyed by healthcare intelligence provider...

Wilmington Healthcare

Working with our healthcare system more closely is vital

Bayer’s Lars Bruening on partnership working amid environmental challenges

- PMLiVE

NICE backs GSK’s €594k gene therapy for rare disease

The treatment offers 'bubble baby' patients an alternative to a stem cell transplant

- PMLiVE

Roche offers diabetes digital health programme to UK patients

Partners with OurPath for its six-week lifestyle management programme

- PMLiVE

What value for innovation in an era dominated by affordability?

Pharma can collaborate but must be clear about its motives

- PMLiVE

Concordia accused of overcharging NHS for thyroid drug

The pharma firm said to have ‘abused’ its position within the UK market

Hunt vs Hawking: We’ll call it a draw

Who won the recent bout between Jeremy Hunt and Stephen Hawking? We'll let you score the cards.

Life Healthcare Communications

What will the NHS’s Capped Expenditure Process (CEP) mean for pharma?

Paul Midgley, Director of NHS Insight at Wilmington Healthcare, explains how pharma should tailor its approach

Wilmington Healthcare

Life at the end of the Brexit tunnel

A new proposal to maintain the UK as a benchmark of excellence in Life Sciences

Life Healthcare Communications

- PMLiVE

Bayer’s Nexavar backed by NICE for liver cancer

The drug is the only approved first-line treatment for advanced HCC

Gilead Sciences

People at-risk of HIV in England could get PrEP from September

10,000 people will use Gilead’s Truvada in the upcoming trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links